Drug-induced liver injury (DILI) is the greatest cause of post-marketing drug withdrawal; therefore, substantial resources are directed towards triaging potentially dangerous new compounds at all stages of drug development. One of the major factors preventing effective screening of new compounds is the lack of a predictive in vitro model of hepatotoxicity. Primary human hepatocytes offer a metabolically-relevant model for which the molecular initiating events of hepatotoxicity can be examined; however, these cells vary greatly between donors and dedifferentiate rapidly in culture. iPSC-derived hepatocyte-like cells offer a reproducible, physiologically-relevant and genotypically-normal model cell; however, current differentiation protocols produce hepatocytelike cells with a relatively immature phenotype. During the reprogramming of somatic cells, the epigenome undergoes dramatic changes; however, this 'resetting' is a gradual process, resulting in an altered differentiation propensity, skewed towards the lineage of origin, particularly in early passage cultures. We therefore performed a comparison of human hepatocyte-and dermal fibroblast-derived iPSCs, assessing the impact of epigenetic memory at all stages of hepatocytelike cell differentiation. These results provide the first isogenic assessment of the starting cell type in human iPSC-derived hepatocyte-like cells. Despite a trend towards improvement in hepatic phenotype in albumin secretion and gene expression, few significant differences in hepatic differentiation capacity were found between hepatocyte and fibroblast-derived iPSCs. We conclude that the donor and inter-clonal differences have a greater influence on the hepatocyte phenotypic maturity than the starting cell type. Therefore, it is not necessary to use human hepatocytes for generating iPSC-derived hepatocyte-like cells.
Introduction
Drug induced liver injury (DILI) confers major clinical burden onto healthcare providers 1, 2 and is the most common cause of post-marketing drug withdrawal 3 , yet a method to accurately predict a toxic liability or model the mechanisms which cause DILI remains elusive. This is in part due to the lack of a translatable in vitro model which reliably triages potentially dangerous compounds during drug development or allows for mechanistic analyses. The gold standard for investigating DILI is the primary human hepatocyte (PHH) due to their metabolic competence; however, PHH dedifferentiate rapidly in culture and vary greatly between donors 4 . Conversely, hepatic cell lines are scalable and readily available but only represent a single (abnormal) genotype and lack metabolic relevance 5 .
Therefore, an expandable, metabolically-relevant, reproducible, population-representative and physiologically/genotypically normal source of cells would be an invaluable resource for investigating and predicting DILI.
One such resource which has the potential to address the role of hepatocytes in hepatotoxicity is induced pluripotent stem cells (iPSC)-derived hepatocyte-like cells (HLCs). Consequently, the generation of HLCs has been an area of intense research since the first differentiation protocols were described in 2004 by Lavon et al 6 . In the intervening years, incremental improvements have been seen in both efficiency of differentiation and phenotype maturity. Despite these improvements, the hepatic phenotype still remains closer to a foetal or neonatal expression profile rather than an adult phenotype [7] [8] [9] . This has led researchers to look elsewhere for improvements in the differentiation of stem cells towards HLCs, including the use of different extracellular substrates 10 , 3D culture systems 11 , small molecules 12 and products of the microbiome 13 .
One further area of interest has been to investigate the cell of origin. Previous work has shown that during the reprogramming process, the hypermethylation of the genes associated with the somatic cell phenotype occurs at a relatively late stage of induced pluripotency 14 . Consequently, induced pluripotent stem cells (iPSCs) maintain a memory of the cell from which they were derived 15 . This phenomenon, termed epigenetic memory, was first described by two separate studies in 2010 16, 17 demonstrating that the starting cell type can influence the differentiation propensity of the iPSC towards the lineage of origin. This was subsequently found to be true of other cell types, such as pancreatic β cells, which demonstrated increased PDX1 and insulin gene expression in spontaneously differentiated iPSCs-derived from β cells when compared to non-β cell-derived iPSCs and ESCs 18 . Epigenetic memory has also been investigated using hepatocytes (table 1) ; however, no study has provided definitive proof of whether the starting cell type significantly impacts upon the hepatic differentiation capacity of iPSCs. Genotype-controlled experiments in mice have shown a transient advantage in HLC gene expression of albumin and CK18 in hepatic-derived iPSCs compared to MEFderived iPSCs 19 . However, this advantage was greater when iPSCs were derived from hepatoblasts than mature hepatocytes and dissipated with time in culture. Liu et al., published the first human comparison in 2011 20 , demonstrating no significant advantage in hepatic phenotype when PHHderived iPSCs were compared to iPSCs derived from other cell types derived from different donors, as measured by albumin secretion, CYP3A activity assays; however, a similar but distinct global epigenetic profile was reported 20 .
More recently, Takayama et al. corroborated the report from Lee et al., 19 in human cells, demonstrating a small but significant advantage when hepatocytes were compared to other cell types; however, the cells were sourced from different donors and the advantage was again found to dissipate with time in culture 21 . The importance of donor-dependent genetic differences was further highlighted by Kajiwara et al. , who showed that donor differences were the largest determinant of hepatocyte-like cell quality, rather than the cell of origin, although this study did not use PHHderived iPSCs 22 .
Therefore, the investigation of epigenetic memory in hepatocyte-like cells can only be truly assessed using a comparison of human genotype-controlled iPSCs derived from hepatocytes and nonhepatocytes isolated from the same donor. Herein, we describe the comparison of isogenic PHHand dermal fibroblast derived iPSCs and the hepatic differentiation potential of these cells. 
Methods

Primary human hepatocyte and dermal fibroblast isolation and culture
Liver and skin resections were received as surgical waste (Aintree hospital, Liverpool, United Kingdom) with full patient consent and ethical approval from the relevant institutional review boards (National Research Ethics Service REC ref: 11/NW/0327). Primary human hepatocytes were isolated using a modified version of the previously described 2-step collagenase method as previously described 23 .
Human dermal fibroblasts (HDFs) were isolated using a previously published protocol 24 . Skin biopsies were cut using scalpel and forceps into approximately 1cm 2 pieces and placed into a 6 well plate (3 pieces/well). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Media was changed daily and colonies formed from day 21 onwards.
iPSCs were maintained on either MEF-coated plates in DMEM/F12 media supplemented with 20%
(v/v) KnockOut serum replacement media, 1x non-essential amino acids, 50µM 2-mercaptoethanol and 0.5% (v/v) penicillin/streptomycin or on Matrigel in Essential 8 medium. All early passage comparison assays were performed using <p10 (donors 1 and 2) or <p15 (donor 3) iPSCs.
Characterisation was performed using iPSCs >p15 and late passage analysis was conducted using iPSCs >p30.
Differentiation to hepatocyte-like cells
Cells were transferred to Matrigel culture 1:1 from MEF culture and cultured in Essential 8 medium. (Table S3 ). Samples were collected in QIAzol (QIAgen), and extracted using the miRNeasy extraction kit according to the manufacturer's protocol (QIAgen) Extracted RNA content was measured using the NanoDrop spectrophotometer (Thermo Fisher Scientific). RNA was reverse transcribed to complementary DNA (cDNA) using the ImProm-II reverse transcription kit (Promega).
Spontaneous differentiation assays
Due to low RNA yield following extraction, whole transcriptome amplification was performed on selected samples using the QuantiTect Whole Transcriptome Kit (Qiagen), following the manufacturer's protocol. Briefly, 100ng of starting RNA from each sample was mixed with reverse transcriptase kit component and incubated at 37°C for 30 minutes and 95°C for 5 minutes. Ligation mix was then added to each samples and incubated for 2 hours at 22°C. Finally, the amplification mix was added and incubated for 8 hours at 30°C and 5 minutes at 95°C. Temperature controlled steps were carried out using the GeneAmp PCR system 9700 thermal cycler system (Applied Biosystem, Waltham, MA) and amplification confirmed using the NanoDrop spectrophotometer.
Gene expression analysis was performed using the SYBRGreen JumpStart Taq ReadyMix (Sigma Aldrich). Briefly, 10-100µg of cDNA was amplified by qRT-PCR as follows: 95°C for 10 minutes, then 40 cycles for 95°C 15 seconds and 60°C for 60 seconds using the ViiA7 qRT-PCR machine (Applied Biosystems). Results were calculated using the C T values generated, normalised against GAPDH or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and succinate dehydrogenase (SDHA) 25 and calculated relative to a calibrator sample (e.g. PHH) using 2 -∆∆CT method 26 . Sendai virus expression analysis of iPSCs was conducted using the TaqMan iPSC Sendai Detection Kit (Life Technologies) according the manufacturer's instructions. Results were normalised using GAPDH and calculated relative to the reprogramming plate using 2 -∆∆CT method. 
Results
Generation of iPSCs derived from PHH and HDFs of multiple donors.
To assess the differences between hepatocyte-like cells differentiated from PHH-and HDF-derived iPSCs, a reprogramming technique capable of inducing pluripotency in both cell types was required.
Reprogramming of PHH has been reported as relatively inefficient compared to more traditionally used cell types, such as HDFs 27 . Therefore, a technique capable of reprogramming PHH was first optimised.
PHH are known not to respond well to trypsinisation and re-plating, therefore it was hypothesised that developing a protocol which did not require re-plating would be the most successful route.
Furthermore, given that the cell cycle is a vital component of reprogramming 28 , the media composition described by Liu et al., 29 which contains high levels of known mitogenic factors HGF and EGF, was used ( Figure S1a ).
Using these conditions, PHH were transduced with the OSKM-containing Sendai viruses at MOI 5 and 10 and examined during the reprogramming period for colony formation ( Figure S2a ). At day 20, the first colonies were noted with similar, but incomplete iPSC-like morphology. These colonies appeared to be heterogeneous and underwent growth arrest during the culture period ( Figure S2a ).
At day 24, one colony was noted which exhibited the hallmark features of an iPSC colony ( Figure   S2b ). After tracking the colony over several days, the colony remained homogenous and continued to expand. This colony was manually picked for expansion and fully characterised.
Using this protocol, iPSCs were successfully generated from hepatocyte cultures from three separate donors ( Figure 1 and Table S4 ). Subsequent to successful PHH-reprograming, the dermal fibroblasts of the corresponding donors were also reprogrammed using a well-established dermal fibroblast protocol ( Figure S1b ). Pluripotency was assessed using a panel of embryonic stem cell-enriched markers: Oct4, Sox2, Nanog, Tra-1-60 and SSEA-4 ( Figure S3 ). All lines examined demonstrated expression of each of the markers, indicating that they had established a pluripotent expression profile.
The functional differentiation capacity of these lines was also assessed using embryoid body (EB)
assays. This assay encourages cellular differentiation and, if truly pluripotent, should result in differentiation towards cell types from all three germ layers: ectoderm, mesoderm and endoderm.
The presence of each of these germ layers within the differentiated cell population was investigated by immunofluorescence, using the markers TUJ1 (Neuron-specific class III beta-tubulin; ectoderm), α-SMA (alpha smooth muscle actin; mesoderm) and AFP (Alpha-Fetoprotein; endoderm) ( Figure S4 ). All of the iPSC lines generated stained successfully for these markers, indicating that all selected lines were functionally pluripotent.
Donor-dependent differences in PHH-and HDF-derived iPSCs gene expression profile.
To fully compare the iPSCs generated from PHH and HDFs, comparisons were required at all stages of culture and differentiation. Therefore, the expression of important pluripotency-associated genes at the iPSC-stage was compared. Across these markers, Oct4 and Nanog showed similar levels of expression between both cell types of origin. Sox2 expression was significantly greater in the PHHderived lines for donor 3; however, this was not true of donors 1 and 2 ( Figure 2a) . Furthermore, analysis of Wnt3, which has been proposed as an iPSC marker of definitive endoderm potential (i.e.
high Wnt3 expression correlates with high purity D.E formation) 30 , again showed no significant differences between PHH and HDF-derived iPSCs; however, a donor-dependent difference was observed ( Figure S5 ).
HNF4α promoter analysis in PHH-and HDF-derived iPSCs demonstrates a small but consistent celltype specific difference in methylation which decreases with time in culture.
As the inherent memory of iPSCs is reported to be a consequence of incomplete epigenetic reprogramming, the potential differences seen between PHH-and HDF-derived lines at the iPSC stage were investigated. In this context, we assessed the methylation status of key hepatic genes:
HNF4α and FOXA2, since their epigenetic status would likely influence the differentiation status of the HLCs. During the process of reprogramming, the methylation of HNF4α and FOXA2 promoter regions in both PHH and HDFs was significantly increased to similar levels between PHH and HDFderived clones (Figure 2b ). We assessed global methylation utilising an assay for LINE1 (Long interspersed nuclear elements retrotransposable element 1) which is repeated throughout the genome and therefore often used as a surrogate marker of whole genome methylation status 31 . Our results indicated very similar global methylation indexes between PHH-and HDF-derived iPSCs (65.35% and 65.43%, respectively; Figure 2b ).
Notwithstanding the global methylation similarity, across the five CpG sites examined within the HNF4α promoter region, each site was consistently ~1% less methylated in the PHH-derived lines when compared to the HDF-derived lines (Figure 2c ). Across all lines and CpG sites investigated, 1.22% less methylation was observed in PHH-derived samples; however, this trend was found to decrease with time in culture, with a difference of 0.42% methylation between late passage PHHderived and HDF-derived iPSCs (Figure 2d ). No conserved methylation differences were found 
Spontaneous differentiation of PHH-and HDF-derived iPSCs reveals the greatest discriminator
between the iPSCs is the donor, rather than the starting cell type.
To investigate if the cell-type of origin influences the inherent differentiation propensity of iPSCs, the hepatic/endoderm-enriched gene expression of embryoid bodies (EBs) was compared. Using a previously published method for comparing iPSCs of different origins 18 , EBs were generated and cultured in suspension for 16 days. The expression of known endoderm and hepatic markers was then compared.
The results presented in figure 3 suggested a very slight trend towards the enhancement of hepaticassociated gene expression in PHH-derived EBs in five of the genes tested, i.e. Albumin, AFP, SOX17, FOXA2 and CXCR4. However, GATA4 and HNF4α showed a trend towards higher expression in the HDF-derived clones. Despite these trends, only Sox17 showed significantly greater expression in PHH-derived iPSCs, although this difference was only observed in one of the three donors. Taken together there was very little difference in the spontaneous differentiation propensity of PHH and HDF-derived iPSCs across the investigated hepatic and endodermal-associated genes. Indeed, the greatest determinant of gene expression appeared to be the donor, rather than the starting cell type.
Donor-and clonal-dependent variation are a greater influence on the gene expression of hepatocytelike cells than the starting cell type.
The differentiation of iPSCs towards hepatocyte-like cells was achieved using a protocol adapted from previous publications 22, 32 ( Figure S6a ) and successful differentiation was confirmed by immunofluorescence at each stage: definitive endoderm (D.E; Sox17), hepatic endoderm (H.E; HNF4α) and HLCs (Albumin) ( Figure S6b ).
To fully evaluate the differentiation procedure and to assess any inherent advantage as a result of the different starting cell types, we compared the gene expression at each stage of differentiation. Figure S7a demonstrates a comparison of several key markers of definitive endoderm. The results followed a similar pattern to previous analysis, demonstrating no significant differences between starting cell types when the gene expression of FOXA2, SOX17 and GATA4 was compared.
Interestingly, both GATA4 and FOXA2, showed a larger dependence on the donor of origin than starting cell type. 
Functional comparisons show no significant difference between PHH-and HDF-derived hepatocytelike cells.
To assess the functional capacity of the HLCs, albumin secretion was compared at day 22 of differentiation. The data demonstrated a non-significant trend pointing towards PHH-derived clones having slightly higher, but non-significantly different, albumin secretion in two of the three donors ( Figure 5a ). When examined together, the difference between PHH-and HDF-derived HLC albumin secretion was not statistically significant ( Figure 5b ).
CYP3A and CYP2D6 activity was also assessed using probe substrates testosterone and dextromethorphan, respectively (Figure 5c and d) . Again, no significant differences were found between the HLCs derived from the different starting cell types. 
Discussion
In this study, we have investigated the hepatocyte differentiation potential of PHH-and HDF-derived iPSCs derived from the same donor in a multi-faceted panel of assays, to give a thorough comparison of the hepatic phenotype.
Our main hypothesis, that the starting cell type influences the differentiation capacity of the cell, was driven by the reported epigenetic memory which remains from the somatic cell following reprogramming 16, 17 . Our results suggested a small but statistically non-significant epigenetic memory may be found in the developmentally important liver-enriched transcription factor HNF4α promoter region in reprogrammed cells derived from human hepatocytes 34, 35 . This is in contrast to 25% difference in the methylation of the PDX1 gene promoter region reported between betapancreatic cell-derived iPSC and non-beta-pancreatic cell-derived iPSCs 18 . Throughout the analysis, a general trend towards a slight, non-significant advantage, to starting with primary human hepatocytes, when compared to dermal fibroblasts, was also noted. This was most evident with HNF4α expression at the hepatic endoderm stage of differentiation. Therefore, the slightly enhanced phenotype in PHH-derived iPSCs at the HLC stage may be driven by the small differences in the methylation patterns of HNF4α reported in this study and other hepatic-associated genes.
Moreover, the lack of a clear enhancement in cell differentiation, as described in pancreatic beta cell-derived iPSCs 18 , may be a consequence of the relatively small differences in the epigenetic profile of PHH-and HDF-derived iPSCs. Our findings that the noted differences in HNF4α methylation decrease with time in culture are in keeping with previous literature, which has demonstrated that the distinct epigenetic patterns and enhanced phenotype in a given cell type-derived iPSC are lost following repeat passaging 16, 17, 19, 21 .
Throughout this study, few significant differences were found between the PHH-and HDF-derivediPSCs. Recent work has suggested that the major determinant in hepatocyte-like cell differentiation phenotype is the donor 22 . This was found to be true for the gene expression analysis of the iPSC, definitive endoderm and embryoid body samples. The gene expression profile of HLCs has been reported to be influenced by the genotype of the corresponding donor PHH 21, 36 . Therefore, to reduce genotype-derived donor variation and allow for a more representative comparison of the starting cell type, HLC samples were compared to the corresponding donor's PHH. Despite this analytical approach, no significant differences were found between PHH-and HDF-derived HLCs.
Whilst the donor appears to be a major determinant of phenotype, other non-defined factors, not related to starting cell type or donor, also appear to influence the hepatic differentiation capacity of however, when all lines were compared, no significant differences were seen between PHH-and HDF-derived lines. This was in part due to the donor 1 HDF-derived line, Liv4FA, which displayed much greater albumin secretion and gene expression than all other lines. If Liv4FA is not included in the analysis, there is significantly greater HLC albumin secretion in lines derived from PHH. Thus, our results suggest that both donor-and clone-dependent variation has greater influence on HLC phenotype than the starting cell type. Further work is therefore required to define the differences between iPSC clones which infer the capacity for hepatic differentiation.
Previous work has described the reprogramming of human hepatocytes as being relatively inefficient compared to HDFs and that it was only achievable with cells derived from relatively young donors 27 .
In contrast, we were able to generate clones from donors which were comparatively old, i.e. 63 and 66 years old. Interestingly, despite using only four clones for the analysis, we were able to generate 10 clones from donor 3 (27 years old). These data point towards an enhancement of hepatocyte reprogramming efficiency in younger donors. The effect of age has been discussed in depth in other starting cell types; with multiple studies in mice showing a decline in reprogramming efficiency with age 37 . However, the effect of age on reprogramming efficiency in human cells is more difficult to assess due to the unknown influence of the donor's genetic background. As a consequence the effect of age is under debate; Sommers et al., reported no significant correlation between age and efficiency 38 , whereas, Trockovic et al., did find a correlation, in a P21-dependent manner 39 .
The isolation of PHH is relatively well-established; however, the lack of a bona fide cell surface marker and the sensitivity of the cells during the isolation process mean that, to the best of our knowledge, a 100% homogenous population of hepatocytes is not currently achievable. Therefore, there remains a possibility that not all of the iPSC clones derived from the PHH-enriched population were derived from hepatocytes. However, if PHH-derived clones were to be used in future experiments, the inability to guarantee a homogenous starting population of hepatocytes will likely remain; therefore, this work is also representative of the practical limitations associated with PHH as a starting cell source.
It must also be acknowledged that the slight enhancements seen in PHH-derived clones may well be limited by the restricted differentiation maturity which is currently achievable in simple 2D HLC culture systems, as used in this study. In line with this, our PHH-derived iPSCs do appear to show a significant trend ( Figure S6b ) towards enhancement of phenotype at the hepatic endoderm stage which is carried through to our HLC analysis. Previous work in mice has shown that the greatest Taken together, the lack of any major advantage to PHH-derived iPSCs is of significance to the field of iPSC-derived HLCs, suggesting that any trend towards enhanced expression in PHH-derived clones is not greater than the inter-clone and donor variation derived from other non-defined influencing factors. Furthermore, the access and phenotypic range of available PHH samples is very restricted in comparison to the easily accessible skin or blood samples used in the majority of current studies 24, 40 .
Therefore, the similarity between the cell types for all tested parameters is reassuring for current and future studies, particularly those which require specific genotypic backgrounds, i.e. for disease studies, or a large phenotypic range for population-representative studies. 
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